CD4+ follicular helper T cell infiltration predicts breast cancer survival

Chunyan Gu‐Trantien(Center of Molecular Immunology (Cuba)), Sherene Loi(Breast Cancer Research Foundation), Soizic Garaud(Center of Molecular Immunology (Cuba)), Carole Equeter(Breast Cancer Research Foundation), Myriam Libin(Center of Molecular Immunology (Cuba)), Alexandre de Wind, Marie Ravoet(Center of Molecular Immunology (Cuba)), Hélène Le Buanec(Center of Molecular Immunology (Cuba)), Catherine Sibille(Center of Molecular Immunology (Cuba)), Germain Manfouo-Foutsop(Center of Molecular Immunology (Cuba)), Isabelle Veys(Université Libre de Bruxelles), Benjamin Haibe‐Kains(Breast Cancer Research Foundation), Sandeep K. Singhal(Breast Cancer Research Foundation), Stefan Michiels(Breast Cancer Research Foundation), Françoise Rothé(Breast Cancer Research Foundation), Roberto Salgado, Hugues Duvillier(Center of Molecular Immunology (Cuba)), Michail Ignatiadis(Breast Cancer Research Foundation), Christine Desmedt(Breast Cancer Research Foundation), Dominique Bron, Denis Larsimont, Martine Piccart(Université Libre de Bruxelles), Christos Sotiriou(Breast Cancer Research Foundation), Karen Willard‐Gallo(Center of Molecular Immunology (Cuba))
Journal of Clinical Investigation
June 16, 2013
Cited by 1,046

Abstract

CD4⁺ T cells are critical regulators of immune responses, but their functional role in human breast cancer is relatively unknown. The goal of this study was to produce an image of CD4⁺ T cells infiltrating breast tumors using limited ex vivo manipulation to better understand the in vivo differences associated with patient prognosis. We performed comprehensive molecular profiling of infiltrating CD4⁺ T cells isolated from untreated invasive primary tumors and found that the infiltrating T cell subpopulations included follicular helper T (Tfh) cells, which have not previously been found in solid tumors, as well as Th1, Th2, and Th17 effector memory cells and Tregs. T cell signaling pathway alterations included a mixture of activation and suppression characterized by restricted cytokine/chemokine production, which inversely paralleled lymphoid infiltration levels and could be reproduced in activated donor CD4⁺ T cells treated with primary tumor supernatant. A comparison of extensively versus minimally infiltrated tumors showed that CXCL13-producing CD4⁺ Tfh cells distinguish extensive immune infiltrates, principally located in tertiary lymphoid structure germinal centers. An 8-gene Tfh signature, signifying organized antitumor immunity, robustly predicted survival or preoperative response to chemotherapy. Our identification of CD4⁺ Tfh cells in breast cancer suggests that they are an important immune element whose presence in the tumor is a prognostic factor.


Related Papers